Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19

Li, Ming; Yu, Tongya; Zhu, Jinghua; Wang, Yinjia; Yang, Yumei; Zhao, Kaiwu; Yi, Yongning; He, Jilin; Li, Chao

doi:10.21037/apm-21-400

Cited by 8 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After treating with integrated Chinese medicine and Western medicine, the results showed that the median time of PCR conversion was 10 days, and the median of hospitalization time was 14 days. A previous study showed nasopharyngeal specimen negative conversion time, and the length of hospitalization of COVID-19 patients in the Arbidol group was 18.50 and 23.52 days, respectively (22). Another study showed that the mean duration of viral clearance was 23.42 days (23).…”

Section: Discussionmentioning

confidence: 98%

Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China

Huang

Li²,

Li³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas at First Affiliated Hospital of Xiamen University from April 1, 2021 to July 31, 2021. These patients received therapy of integrated Chinese medicine and western medicine. Demographic data and clinical characteristics were extracted and analyzed. In addition, the prescription which induced less length of PCR positive days and hospitalization days than the median value was obtained. The top 4 frequently used Chinese medicine and virus-related genes were analyzed by network pharmacology and bioinformatics analysis. According to the chest computed tomography (CT) measurement, abnormal lung findings were observed in 145 subjects. The median length of positive PCR/hospitalization days was 7/7 days for asymptomatic subjects, 14/24 days for mild subjects, 10/15 days for moderate subjects, and 14/20 days for severe subjects. The most frequently used Chinese medicine were Scutellaria baicalensis (Huangqin), Glycyrrhiza uralensis (Gancao), Bupleurum chinense (Chaihu), and Pinellia ternata (Banxia). The putative active ingredients were baicalin, stigmasterol, sigmoidin-B, cubebin, and troxerutin. ACE, SARS-CoV-2 3CL, SARS-CoV-2 Spike, SARS-CoV-2 ORF7a, and caspase-6 showed good binding properties to active ingredients. In conclusion, the clinical results showed that integrated Chinese medicine and Western medicine are effective in treating COVID-19 patients from overseas. Based on the clinical outcomes, the putative ingredients from Chinese medicine and the potential targets of SARS-CoV-2 were provided, which could provide a reference for the clinical application of Chinese medicine in treating COVID-19 worldwide.

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China

Huang

Li²,

Li³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…This may indicate that the anti-SARS-CoV-2 bio-properties of Arbidol arise from several biochemical pathways [ 94 ]. Clinical studies have confirmed the suitability of Arbidol as a monotherapy or in combination with other therapeutics for COVID-19 patients [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 ]. Some countries (e.g., Russia, China, and Iran [ 95 ]) have awarded licenses to Arbidol for the prevention or treatment of COVID-19 [ 115 ].…”

Section: Repurposed Indole-containing Drugsmentioning

confidence: 99%

Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2

Girgis,

Panda,

Kariuki

et al. 2023

Molecules

View full text Add to dashboard Cite

The COVID-19 pandemic has posed a significant threat to society in recent times, endangering human health, life, and economic well-being. The disease quickly spreads due to the highly infectious SARS-CoV-2 virus, which has undergone numerous mutations. Despite intense research efforts by the scientific community since its emergence in 2019, no effective therapeutics have been discovered yet. While some repurposed drugs have been used to control the global outbreak and save lives, none have proven universally effective, particularly for severely infected patients. Although the spread of the disease is generally under control, anti-SARS-CoV-2 agents are still needed to combat current and future infections. This study reviews some of the most promising repurposed drugs containing indolyl heterocycle, which is an essential scaffold of many alkaloids with diverse bio-properties in various biological fields. The study also discusses natural and synthetic indole-containing compounds with anti-SARS-CoV-2 properties and computer-aided drug design (in silico studies) for optimizing anti-SARS-CoV-2 hits/leads.

show abstract

“…Figure 1 shows the literature search flow, removal of duplicates, and the screening based on title, abstract, and full text. As a result, 52 full-text articles were reviewed and sixteen studies 24,[32][33][34][35][36][37][38][39][40][41][42][43][44][45][46] entered the final analysis. The characteristics of the studies included in the systematic review are presented in Table 1.…”

Section: The Characteristics Of Studiesmentioning

confidence: 99%

Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis

Amani

Zareei

et al. 2021

Immunity Inflam & Disease

View full text Add to dashboard Cite

Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa scale were used to assess the quality of included studies. Meta‐analysis was performed using RevMan 5.3. Results Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non‐antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR‐PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78–1.14) and Day 14 (RR: 1.10; 95% CI: 0.96–1.25), and PCR negative conversion time (PCR‐NCT; mean difference [MD]: 0.74; 95% CI: −0.87 to 2.34), nor secondary outcomes ( p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06–4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes ( p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR‐PCR on Day 7 and PCR‐NCT ( p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes ( p > .05). No remarkable therapeutic effect was observed between arbidol and other agents ( p > .05). Conclusion The present meta‐analysis showed no significant benefit of using arbidol compared with non‐antiviral treatment or other therapeutic agents against COVID‐19 disease. High‐quality studies are needed to establish the efficacy and safety of arbidol for COVID‐19.

show abstract

Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19

Cited by 8 publications

References 17 publications

Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China

Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China

Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2

Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis

Contact Info

Product

Resources

About